Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2025 Jan;30(1):51-61.
doi: 10.1111/resp.14822. Epub 2024 Aug 28.

Safety and efficacy of a novel transbronchial radiofrequency ablation system for lung tumours: One year follow-up from the first multi-centre large-scale clinical trial (BRONC-RFII)

Changhao Zhong  1 , Enguo Chen  2 , Zhuquan Su  1 , Difei Chen  1 , Feng Wang  3 , Xiaoping Wang  4 , Guangnan Liu  5 , Xiaoju Zhang  6 , Fengming Luo  7 , Nan Zhang  8 , Hongwu Wang  9 , Longyu Jin  10 , Fa Long  11 , Chunfang Liu  12 , Shiman Wu  13 , Qing Geng  14 , Xiang Wang  15 , Chunli Tang  1 , Ruchong Chen  1 , Felix J F Herth  16 , Jiayuan Sun  17 , Shiyue Li  1
Affiliations
Clinical Trial

Safety and efficacy of a novel transbronchial radiofrequency ablation system for lung tumours: One year follow-up from the first multi-centre large-scale clinical trial (BRONC-RFII)

Changhao Zhong et al. Respirology. 2025 Jan.

Abstract

Background and objective: Radiofrequency ablation (RFA) is an emerging treatment of lung cancer, yet it is accompanied by certain safety concerns and operational limitations. This first multi-centre, large-scale clinical trial aimed to investigate the technical performance, efficacy and safety of an innovative transbronchial RFA system for lung tumours.

Methods: The study enrolled patients with malignant lung tumours who underwent transbronchial RFA using an automatic saline microperfusion system between January 2021 and December 2021 across 16 medical centres. The primary endpoint was the complete ablation rate. The performance and safety of the technique, along with the 1-year survival rates, were evaluated.

Results: This study included 126 patients (age range: 23-85 years) with 130 lung tumours (mean size: 18.77 × 14.15 mm) who had undergone 153 transbronchial RFA sessions, with a technique success rate of 99.35% and an average ablation zone size of 32.47 mm. At the 12-month follow-up, the complete ablation rate and intrapulmonary progression-free survival rates were 90.48% and 88.89%, respectively. The results of patients with ground-glass nodules (GGNs) were superior to those of the patients with solid nodules (12-month complete ablation rates: solid vs. pure GGN vs. mixed GGN: 82.14% vs. 100% vs. 96.08%, p = 0.007). No device defects were reported. Complications such as pneumothorax, haemoptysis, pleural effusion, pulmonary infection and pleural pain were observed in 3.97%, 6.35%, 8.73%, 11.11% and 10.32% of patients, respectively. Two subjects died during the follow-up period.

Conclusion: Transbronchial RFA utilizing an automatic saline microperfusion system is a viable, safe and efficacious approach for the treatment for lung tumours, particularly for patients with GGNs.

Keywords: bronchoscopy; ground‐glass nodule; lung tumour; radiofrequency ablation.

PubMed Disclaimer

Conflict of interest statement

This trial is sponsored by Broncus Medical Co. The funders and sponsors of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The authors have no conflicts of interest to declare.

Figures

FIGURE 1
FIGURE 1
The flowchart of patient enrollment and follow‐up process.
FIGURE 2
FIGURE 2
CT images acquired for preoperative evaluation and of the surgical procedure. (A): CT images acquired for preoperative evaluation. Red arrow: Target lesion. (B): Cone‐beam CT images of intraoperative electrode positioning. Red arrow: Target lesion and RFA electrode. (C): Cone‐beam CT images acquired immediately after ablation. Red arrow: Target ablation zone. (D–H): CT images acquired at 24 h, 1 month, 3 months, 6 months, 12 months. Red arrow: Target ablation zone.
FIGURE 3
FIGURE 3
Kaplan–Meier survival curves of intrapulmonary progression‐free survival. (A): Subgroup analysis of lesions <2 cm and 2–3 cm in size. (B): Subgroup analysis of solid nodules with ground‐glass nodule.
See this image and copyright information in PMC

References

    1. Gedvilaite V, Danila E, Cicenas S, Smailyte G. Lung cancer survival in Lithuania: changes by histology, age, and sex from 2003‐2007 to 2008‐2012. Cancer Control. 2019;26(1):1147271349. - PMC - PubMed
    1. Gould MK, Donington J, Lynch WR, Mazzone PJ, Midthun DE, Naidich DP, et al. Evaluation of individuals with pulmonary nodules: when is it lung cancer? Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence‐based clinical practice guidelines. Chest. 2013;143(5 Suppl):e93S–e120S. - PMC - PubMed
    1. Casal RF, Tam AL, Eapen GA. Radiofrequency ablation of lung tumors. Clin Chest Med. 2010;31(1):151–163. - PubMed
    1. Hong K, Georgiades C. Radiofrequency ablation: mechanism of action and devices. J Vasc Interv Radiol. 2010;21(8 Suppl):S179–S186. - PubMed
    1. Dupuy DE, Zagoria RJ, Akerley W, Mayo‐Smith WW, Kavanagh PV, Safran H. Percutaneous radiofrequency ablation of malignancies in the lung. AJR Am J Roentgenol. 2000;174(1):57–59. - PubMed

MeSH terms